Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome 6th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology Anger, J. T., Zabihi, N., Clemens, J. Q., Payne, C. K., Saigal, C. S., Rodriguez, L. V. SPRINGER LONDON LTD. 2011: 395–400

Abstract

In order to better understand provider treatment patterns for interstitial cystitis (IC)/painful bladder syndrome, we sought to document the therapies utilized and their associated expenditures using a national dataset.A cohort was created by applying the ICD-9 diagnosis of IC (595.1) to INGENIX claims for the year 1999. Subjects were followed for 5 years, and patterns of care and related expenditures were evaluated.Of 553,910 adults insured in 1999, 89 subjects had a diagnosis of IC with 5-year follow-up data. All subjects were treated with oral medication(s), 26% received intravesical treatments, and 22% underwent hydrodistension. Total expenditures per subject were $2,808.The majority of IC expenditures were attributable to oral medical therapy. Hydrodistension and intravesical instillations were utilized in less than 25% of patients. Hydrodistension was used more frequently among subjects with a new diagnosis; this may reflect its utilization as part of a diagnostic algorithm.

View details for DOI 10.1007/s00192-010-1252-8

View details for Web of Science ID 000288173700004

View details for PubMedID 20811877

View details for PubMedCentralID PMC3051069